Welcome to our dedicated page for Blade Air Mobility SEC filings (Ticker: BLDE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Strata Critical Medical, Inc., formerly Blade Air Mobility, Inc., files regulatory documents that document the company's transition from a broader air mobility platform to a critical medical business. The filings cover the completed Passenger business disposition, the corporate name change, Nasdaq-listed common stock under SRTA, and warrant-related capital-structure actions, including a Form 25 for removal of warrants from listing and registration.
Its 8-K reports and proxy materials disclose operating results from continuing operations, logistics and clinical revenue categories, material agreements, acquisition activity, credit arrangements involving operating subsidiaries such as Trinity Air Medical and Keystone Perfusion Services, and annual meeting governance matters. The record also includes exhibit filings, Inline XBRL cover data, and stockholder voting disclosures tied to the rebranded issuer.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen reported compensation-related equity activity involving performance-based restricted stock units (PSUs). On April 23, he acquired 83,505 shares of Class A common stock at no cost upon certification that PSU performance criteria from a March 20, 2025 grant were met. On April 24, 40,960 shares were withheld by the company at $4.92 per share to cover tax withholding obligations tied to the PSU vesting. After these routine award and tax-withholding entries, Cohen directly holds 216,444 shares of Class A common stock.
Strata Critical Medical, Inc. director and Co-CEO/General Counsel Melissa M. Tomkiel reported equity compensation activity in Class A common stock. On April 23, 2026, she acquired 630,264 shares at $0.00 per share from the vesting of performance-based restricted stock units. On April 24, 2026, 321,750 shares were disposed of at $4.92 per share, representing shares withheld by the company to cover tax obligations related to that vesting, not an open-market sale. After these transactions, she directly held 1,922,504 shares of Class A common stock.
Strata Critical Medical, Inc. Co-CEO and CFO William A. Heyburn reported equity compensation activity involving the company’s Class A common stock. On April 23, 2026, he acquired 545,625 shares at $0.0000 per share upon vesting of performance-based restricted stock units granted on March 20, 2025, after the compensation committee certified that performance criteria were met.
On April 24, 2026, 301,731 shares were disposed of at $4.92 per share through shares withheld by the issuer to cover tax withholding obligations related to the PSU vesting, rather than an open-market sale. Following these transactions, Heyburn directly held 1,580,668 shares of Class A common stock.
Strata Critical Medical, Inc. calls a virtual 2026 annual stockholder meeting on May 28, 2026 at 9:00 a.m. Eastern to elect two Class II directors, ratify Deloitte & Touche LLP as auditor, and hold an advisory Say‑on‑Pay vote on 2025 executive compensation.
The company, formerly Blade Air Mobility, transformed in 2025 into a pure‑play medical logistics and services provider by selling its passenger business to Joby Aviation for approximately $76 million in Joby stock plus up to $45 million in holdbacks and earn‑outs, and acquiring Keystone Perfusion Services. It now operates Logistics and Clinical segments serving transplant and cardiovascular surgery customers.
Governance highlights include a classified Board, Co‑Chief Executive Officers William A. Heyburn and Melissa M. Tomkiel, and former CEO Robert Wiesenthal as Non‑Executive Chairman, with independent director Andrew Lauck expected to become Lead Independent Director after the meeting. The compensation program emphasizes pay for performance through cash bonuses tied mainly to Adjusted EBITDA and performance stock units.
Velibor Krstic filed an amended Schedule 13D reporting a significant warrant position in Strata Critical Medical, Inc. He beneficially owns 1,139,393 warrants, representing about 12.4% of the 9,166,644 public warrants outstanding as of the issuer’s latest annual report.
Krstic is a Swiss private investor who used approximately 19,380 dollars of personal funds to acquire these warrants, including 374,958 warrants bought on April 8, 2026 at a weighted average price of about 0.011 dollars per warrant. He also holds 26,425 shares of common stock, or roughly 0.03% of the 86,989,143 shares outstanding as of February 24, 2026.
He states that the warrants are significantly undervalued relative to the company’s fundamentals, citing Adjusted EBITDA of 14.1 million dollars and the integration of Keystone Perfusion. Krstic intends to monitor board and management decisions before the May 7, 2026 warrant expiration and may discuss potential actions such as a voluntary exchange offer or amendments to the warrant agreement, while noting no concrete plans under the specified regulatory categories.
Strata Critical Medical, Inc. investor Velibor Krstic filed a Schedule 13D after accumulating 764,435 public warrants to purchase Class A common stock. These warrants represent about 8.3% of the 9,166,644 public warrants outstanding, bought in Nasdaq open-market trades for roughly $15,231 of personal funds.
Krstic reports holding sole voting and dispositive power over all the warrants and states he acquired them for investment purposes, believing the SRTAW warrants are undervalued relative to the issuer’s fundamentals, including Adjusted EBITDA of $14.1 million and the integration of Keystone Perfusion. He indicates he may engage with the board, management, sponsor KSL Capital Partners, and other holders before the warrants’ May 7, 2026 expiration, potentially discussing actions such as a voluntary exchange offer or amendments to the Warrant Agreement.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen reported routine share dispositions related to tax withholding on vested restricted stock units. On September 4, 2025 and September 10, 2025, the issuer withheld a total of 9,190 shares of Class A common stock to satisfy tax obligations. After these withholdings, Cohen directly owns 94,570 shares. This amended filing corrects an earlier Form 4 that had overstated his direct beneficial ownership by 5,483 shares due to an omitted tax-withholding entry.
Wunsch Scott M reported acquisition or exercise transactions in this Form 4 filing.
Strata Critical Medical, Inc. CEO Scott M. Wunsch received an equity award of 18,067 restricted stock units tied to the company’s Class A common stock. The RSUs were granted at no cash cost to him as part of his quarterly commission program.
All 18,067 RSUs vest on June 8, 2026, provided he continues serving the company, and will be settled in shares upon vesting. After this grant, he holds 587,874 shares directly and 382,987 shares indirectly through a limited liability company of which he is the sole member.
Strata Critical Medical, Inc. reported a Form 4 for officer Scott M. Wunsch, CEO of Trinity Air Medical. On March 8, 2026, 3,631 shares of Class A common stock were withheld by the company to cover tax obligations from restricted stock unit vesting, a non-market disposition. After this, Wunsch held 569,807 shares directly and 382,987 shares indirectly through a limited liability company of which he is the sole member.
Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen reported a routine tax-withholding transaction. The issuer withheld 2,433 shares of Class A common stock at $4.54 per share to satisfy taxes on vested restricted stock units, and Cohen now directly holds 179,384 shares.